On the disclosed annual basis, revenue rose from KRW 1.43 trillion in 2022 to KRW 1.51 trillion in 2023 (up 5.8%), KRW 1.64 trillion in 2024 (up 8.3%) and KRW 1.66 trillion in 2025 (up 1.1%).
Revenue has increased for three consecutive years from 2023 through 2025, and 2025 was the largest year in the 2022 to 2025 span. Operating profit peaked at KRW 42.1 billion in 2023 (up 10.0%), fell to KRW 30.1 billion in 2024 (down 28.5%), and recovered slightly to KRW 31 billion in 2025 (up 3.2%).
The operating margin slipped from 2.7% in 2022 and 2.8% in 2023 to 1.8% in 2024 and 1.9% in 2025, so sales expansion did not translate into margin expansion.
Net income attributable to parent shareholders climbed to KRW 37 billion in 2023 (up 52.9%) and KRW 40.5 billion in 2024 (up 9.5%), then dropped to KRW 21 billion in 2025 (down 48.2%). Net income including non-controlling interests fell from KRW 41.8 billion in 2024 to KRW 21.3 billion in 2025.
Operating cash flow was negative in 2023 and 2024 before turning to KRW 82.3 billion in 2025. By quarter, revenue bottomed at KRW 410.9 billion in Q1 2026 and then rose to KRW 439.8 billion in Q2 and KRW 460.6 billion in Q3, two straight quarters of growth.
Operating profit went from KRW 7.52 billion in Q1 2026 to KRW 2.82 billion in Q2 and then KRW 7.04 billion in Q3, a 149.4% rebound. Q3 revenue rose about KRW 16.1 billion year on year, but cost of sales and selling and administrative expenses rose about KRW 19.9 billion, according to Newsfc.
Pre-tax income was KRW 785 million, well below operating profit; Biotimes reported non-operating losses of about KRW 6.25 billion, and the company did not detail them in its preliminary release.
For the first nine months of 2026 (preliminary), revenue was KRW 1.31 trillion, up 5.1%, operating profit KRW 17.4 billion, down 7.1%, and net income KRW 8.7 billion, down 50.3%.